| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | 0.079 | 0.8 |